Zyban is a non-nicotine, sustained-release form of bupropion designed to help adults quit smoking. It reduces nicotine cravings and the uncomfortable withdrawal symptoms that often derail early quit attempts, such as irritability, difficulty concentrating, restlessness, and depressed mood. By making the transition away from nicotine more manageable, Zyban can significantly improve quit rates, especially when paired with counseling, quitline support, or digital coaching.
Unlike nicotine replacement therapies (NRT) such as patches, gum, or lozenges, Zyban does not supply nicotine. It modulates brain neurotransmitters (primarily norepinephrine and dopamine) thought to be involved in addiction and reward. Many people find Zyban helpful during the critical first weeks of a quit plan and throughout the maintenance period to guard against relapse. It is typically initiated one to two weeks before a planned quit day so therapeutic levels are established in time.
Zyban may be used alone or, in select cases, alongside nicotine replacement. If combined with NRT, blood pressure should be monitored more closely due to a higher risk of hypertension. Your care team can help decide the best approach based on your smoking history, prior quit attempts, and medical profile.
The usual adult dose for smoking cessation is 150 mg once daily for the first 3 days, then 150 mg twice daily thereafter, taken at least 8 hours apart. The maximum recommended daily dose for Zyban is 300 mg. Begin treatment one to two weeks before your chosen quit date to allow the medicine to reach steady levels. Many people continue Zyban for 7 to 12 weeks; some may benefit from a longer course if they are at high risk of relapse, as guided by a clinician.
Take Zyban SR tablets whole with or without food. Do not crush, split, or chew—doing so can increase the risk of side effects, including seizures. To reduce insomnia, avoid taking the second dose near bedtime; aim for morning and mid-afternoon dosing. If you experience persistent sleep problems, discuss adjusting the timing with your healthcare professional rather than changing the dose on your own.
Dosing adjustments may be necessary for certain conditions. In moderate to severe liver impairment, dosing is typically reduced to 150 mg every other day; in mild liver impairment, 150 mg once daily is often used. For renal impairment or in older adults, lower target doses and slower titration may be recommended due to reduced drug clearance. If you do not see meaningful progress by around 7 weeks, your prescriber may reevaluate your plan, which could include behavioral support optimization, medication adjustments, or alternative therapies.
Zyban lowers the seizure threshold, so a careful assessment of personal and family medical history is important before starting. Tell your clinician if you have ever had a seizure, significant head injury, a brain tumor, severe hepatic impairment, or if you drink large amounts of alcohol or use sedatives, benzodiazepines, or stimulants. Abruptly stopping alcohol, benzodiazepines, or barbiturates while starting Zyban increases seizure risk and should be avoided without medical supervision.
Discuss any history of eating disorders, especially bulimia or anorexia nervosa, as these conditions are associated with increased seizure risk and represent a contraindication to Zyban. Also inform your clinician if you have bipolar disorder, a history of mania/hypomania, or significant mood disorders. While many people tolerate Zyban well, monitor for mood changes, anxiety, agitation, or suicidal thoughts—particularly during the first weeks of treatment or when doses change—and seek prompt medical help if these occur.
Blood pressure can rise with bupropion, especially when combined with nicotine patches or other stimulants. If you have hypertension or cardiovascular disease, check your blood pressure regularly. Use caution if you have narrow-angle glaucoma risk, as transient pupillary dilation may precipitate an angle-closure event in susceptible individuals. In pregnancy or while breastfeeding, a personalized risk-benefit discussion is advised. Lastly, Zyban is not for use in children or adolescents for smoking cessation.
Do not use Zyban if you:
• Have a seizure disorder or a current/prior diagnosis of bulimia or anorexia nervosa.
• Are using or have recently used a monoamine oxidase inhibitor (MAOI), including linezolid or intravenous methylene blue; allow at least 14 days between an MAOI and Zyban.
• Are undergoing abrupt discontinuation of alcohol, benzodiazepines, barbiturates, or antiepileptic drugs.
• Have had a serious hypersensitivity reaction to bupropion or any component of the formulation (e.g., anaphylaxis, Stevens–Johnson syndrome).
• Are already taking another bupropion-containing product (e.g., Wellbutrin, Aplenzin, Forfivo), as duplication increases risk of adverse effects and seizures.
Common side effects include insomnia, dry mouth, headache, nausea, dizziness, tremor, constipation, and increased sweating. Many transient effects improve over the first 1 to 2 weeks. Taking the second dose earlier in the day and avoiding late-day caffeine can help with sleep disturbances. Dry mouth can be managed with hydration, sugar-free gum, or saliva substitutes. If nausea occurs, try taking doses with food.
Less common effects include anxiety, agitation, palpitations, tachycardia, and increases in blood pressure. Allergic reactions may present with rash, itching, hives, swelling, or shortness of breath—seek urgent care for signs of a severe reaction. Neuropsychiatric symptoms have been reported during smoking cessation with or without medication; watch for mood changes, depression, hostility, paranoia, hallucinations, or suicidal thoughts, and contact a clinician promptly if these occur.
Seizures are a rare but serious adverse effect, with risk increasing at higher doses, when tablets are crushed/chewed, or when combined with other seizure-threshold–lowering substances. Hepatic dysfunction and visual disturbances are uncommon but possible. Report any persistent or severe side effects to your healthcare professional to evaluate dose timing adjustments, supportive care, or alternative therapies.
Avoid Zyban with monoamine oxidase inhibitors (MAOIs), and do not start Zyban within 14 days of stopping an MAOI due to risk of hypertensive crisis and other serious reactions. Exercise caution with other medicines that lower the seizure threshold, including antipsychotics, tricyclic antidepressants, other antidepressants, tramadol, theophylline, systemic corticosteroids, and stimulants. Abrupt discontinuation of alcohol, benzodiazepines, or sedatives also raises seizure risk.
Bupropion is a strong inhibitor of CYP2D6, which can raise levels of CYP2D6 substrates such as certain SSRIs and SNRIs, tricyclics, antipsychotics, beta-blockers (e.g., metoprolol), type 1C antiarrhythmics (e.g., propafenone, flecainide), and tamoxifen (potentially reducing efficacy). Dose adjustments or monitoring may be necessary when these drugs are coadministered. Agents affecting CYP2B6 can alter bupropion exposure: inhibitors like ticlopidine or clopidogrel can increase bupropion levels, while inducers such as ritonavir, lopinavir, efavirenz, or carbamazepine can decrease them.
Combining Zyban with nicotine replacement therapy may increase the risk of hypertension; monitor blood pressure closely. Limit or avoid alcohol, as unpredictable neuropsychiatric effects can occur and seizure risk may rise. Always provide a complete medication and supplement list—including herbals like St. John’s wort or ginseng—so your clinician can review for interactions specific to your regimen.
If you miss a dose, skip it and take your next dose at the usual time, ensuring at least 8 hours between doses. Do not double up to make up for a missed tablet. Doubling increases the risk of side effects such as insomnia and, more importantly, seizures. Maintaining a consistent schedule and using reminders or pill organizers can help prevent missed doses during the critical early weeks of quitting.
Overdose symptoms may include seizures, severe agitation, hallucinations, loss of consciousness, rapid or irregular heartbeat, fainting, dizziness, vomiting, and changes on an ECG. If an overdose is suspected, call emergency services or poison control immediately. Do not wait for symptoms to worsen. Supportive care in a medical setting may include airway protection, seizure management, cardiac monitoring, and treatment of blood pressure changes. To reduce risk, keep Zyban out of reach of children and pets, never exceed prescribed doses, and avoid combining with other bupropion products.
Store Zyban at room temperature, ideally 20°C to 25°C (68°F to 77°F), protected from moisture and excessive heat. Keep tablets in the original, tightly closed container with the desiccant. Do not store in the bathroom. Do not use tablets that are chipped, crushed, or past the expiration date. Always keep medications out of sight and reach of children and pets, and never share your prescription with others.
In the United States, Zyban (bupropion SR) is a prescription-only medication. While federal and state laws require clinician authorization, Culpeper Regional Health System offers a legal, structured pathway to help adults start therapy even if they do not have a preexisting paper prescription. Through streamlined telehealth evaluations, you can complete a secure intake, meet a licensed clinician, and—if appropriate—receive an electronic prescription that is routed to a partner pharmacy or delivered to your door. This ensures you can buy Zyban without prescription in the traditional sense of a prior office visit, while still meeting all regulatory requirements for safety and oversight.
The process is designed for convenience and compliance: identity verification, eligibility screening (including seizure risk, mental health history, and current medications), blood pressure considerations, and education about proper use. Most adults 18 and older can complete the visit from home. Transparent pricing, cash-pay options, and insurance billing may be available depending on your plan. State-specific rules apply, and availability can vary by location. If Zyban is not appropriate, the clinician will discuss alternatives such as nicotine replacement, varenicline, or behavioral programs. This integrated approach helps you start a quit plan quickly and safely, with ongoing support to maximize your chances of becoming smoke-free.
To prepare for your evaluation, have a list of current medications and supplements, any history of seizures or eating disorders, and recent blood pressure readings. During the session, ask about dose timing to minimize insomnia, how to combine Zyban with counseling or quitlines, and what to expect over the first month. With Culpeper Regional Health System’s coordinated care, you can move from planning to action confidently, with clinical guidance at every step.
Zyban is a brand of sustained‑release bupropion prescribed to help adults quit smoking. It reduces nicotine cravings and withdrawal symptoms so you can focus on behavior change and staying smoke‑free.
Bupropion enhances dopamine and norepinephrine signaling and also blocks certain nicotinic receptors. This combination blunts the reward from smoking and eases withdrawal, making urges less intense and less frequent.
Used with behavioral support, Zyban roughly doubles long‑term quit rates compared with placebo. Success improves further when you set a quit date, take it as directed, and use counseling or a stop‑smoking program.
Adults who smoke daily, want a non‑nicotine medication, and prefer to minimize post‑quit weight gain may benefit. It’s often considered when past attempts with nicotine replacement therapy (NRT) weren’t enough or when a patient prefers a pill.
Do not use Zyban if you have a seizure disorder, a current or past diagnosis of bulimia or anorexia nervosa, are using another bupropion‑containing product, took an MAOI in the past 14 days, or recently stopped heavy alcohol/benzodiazepine use. People with severe liver disease or uncontrolled hypertension need careful assessment and dosing guidance.
Start one week before your quit date: 150 mg once daily for 3 days, then 150 mg twice daily at least 8 hours apart. Take the second dose by late afternoon to reduce insomnia. Do not exceed 300 mg per day unless your clinician directs otherwise.
Set a quit date in the second week of treatment, typically day 8 to 14. Many people notice fewer cravings within the first week, which helps you stop on schedule.
Common effects include insomnia, dry mouth, headache, nausea, jitteriness, and tremor. Less commonly, rash, ringing in the ears, or changes in mood can occur. Most effects are mild and improve over time, but report persistent or severe symptoms.
Bupropion has a dose‑related seizure risk, about 1 in 1,000 at the standard 300 mg/day SR dose. The risk rises with certain conditions and medicines that lower the seizure threshold, so it’s critical to follow dosing instructions and avoid contraindications.
A small number of people may experience mood changes, agitation, anxiety, or suicidal thoughts. Seek medical advice promptly for new or worsening psychiatric symptoms, especially if you have a history of mental health conditions.
Yes, bupropion can increase blood pressure in some people, and the risk is higher if combined with nicotine patches. Check your blood pressure periodically, especially if you have hypertension.
Alcohol can increase the risk of seizures and mood changes while on bupropion. Limit or avoid alcohol and be consistent in your intake if you choose to drink.
Avoid MAOIs and linezolid or IV methylene blue. Bupropion inhibits CYP2D6, which can raise levels of certain antidepressants, antipsychotics, beta‑blockers, and tramadol; it may reduce the effectiveness of tamoxifen. Anticonvulsants, carbamazepine, phenytoin, ritonavir, and some antiretrovirals can alter bupropion levels; discuss all meds and supplements with your clinician.
Yes, many people use Zyban with a patch plus short‑acting gum/lozenge to handle breakthrough cravings. Monitor blood pressure more closely when combining, and coordinate a plan with your clinician.
Data in pregnancy are limited; bupropion may be considered if the expected benefit outweighs risks when non‑pharmacologic methods or NRT are not suitable. Small amounts appear in breast milk; discuss individualized risks and alternatives with your obstetric and pediatric providers.
Skip the missed dose if it’s close to the next one; do not double up. Keep doses about 8 hours apart and avoid evening dosing to minimize insomnia.
A typical course lasts 7 to 12 weeks. Some people continue for several months to reduce relapse risk, especially if cravings persist; your clinician can tailor the duration.
Bupropion is generally weight‑neutral and can modestly reduce early post‑quit weight gain. Pairing it with a nutrition and activity plan provides the best protection against weight gain.
Zyban is approved for adults; safety and efficacy in people under 18 have not been established. Youth should use evidence‑based counseling and age‑appropriate support programs.
Varenicline generally yields higher quit rates than bupropion in head‑to‑head studies. Zyban may be preferred when nausea or vivid dreams with varenicline are problematic, when cost favors generic bupropion SR, or when weight control is a priority.
Both are effective. The patch delivers steady nicotine to curb withdrawal, while Zyban changes brain chemistry and reduces the rewarding effects of smoking. Many quitters do best combining Zyban with a patch plus a rapid NRT (gum/lozenge) for spikes in cravings.
Gum and lozenges treat moment‑to‑moment urges with on‑demand nicotine, whereas Zyban provides background craving control. Using them together can address both steady and breakthrough cravings.
Combination NRT (patch plus a short‑acting form) often matches or exceeds Zyban monotherapy in efficacy. If Zyban alone isn’t enough, adding combination NRT or switching to varenicline are common next steps.
Both contain bupropion, but Zyban is the brand specifically indicated for smoking cessation, typically in the SR 150 mg formulation taken twice daily. Some prescribers use generic bupropion SR with the Zyban dosing schedule; avoid taking any other bupropion product concurrently.
Bupropion XL is once‑daily and not the standard formulation studied for smoking cessation. Some clinicians may use it off‑label for convenience, but SR 150 mg twice daily is the regimen with the most evidence for quitting.
Both can help, but varenicline and combination NRT usually outperform them. Nortriptyline is effective off‑label but has more anticholinergic and cardiac side effects; Zyban is often tried first due to a more favorable tolerability profile.
Cytisine, a plant‑based partial nicotinic agonist available in some regions, improves quit rates and is pharmacologically similar to varenicline at lower cost. Direct comparisons with Zyban are limited, but cytisine generally appears at least as effective as single‑form NRT and may outperform bupropion in some studies.
Zyban combined with a patch can approach varenicline’s effectiveness for some people, though results vary. If you tolerate varenicline well, it tends to provide the highest solo efficacy; if not, Zyban plus combination NRT is a strong alternative.
Zyban is an FDA‑approved medication with well‑defined dosing and safety. Regulated nicotine vaping may help some smokers quit but is not approved as a cessation drug and has uncertain long‑term safety; many guidelines recommend FDA‑approved therapies first.
Medications like Zyban roughly double your chances of long‑term abstinence compared with willpower alone. They make withdrawal more manageable, helping you stick with behavioral changes.
Reputable generics are considered therapeutically equivalent and are widely used. Some individuals perceive differences in release characteristics between manufacturers; if tolerability changes after a switch, discuss trying a different generic or a consistent manufacturer supply.
Zyban more often causes insomnia, dry mouth, and mild anxiety; varenicline more often causes nausea and vivid dreams. Both can affect mood in rare cases; choose based on your side‑effect preferences and medical history.
Zyban has a modest weight‑sparing effect early after quitting, while NRT is generally weight‑neutral. If preventing weight gain is a major concern, Zyban (with nutrition and activity support) can be advantageous, or consider combining Zyban with NRT for efficacy and weight control.
Lets get in touch if you have any questions.